Improving T cell therapies to fight cancer more effectively.
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
This study is looking at ways to make cancer-fighting T cells work better by changing certain genes, and it's for patients who are exploring new treatments for their cancer.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10849895 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of adoptive T cell therapies for cancer treatment by targeting specific genes that regulate T cell behavior. The principal investigator, Dr. Julia Carnevale, is utilizing a novel technology called SLICE, which allows for comprehensive genome screening in T cells to identify genes that can improve their anti-tumor activity. By disrupting genes like SOCS1 and RASA2, which negatively regulate T cell signaling, the research aims to boost the ability of T cells to attack cancer cells more effectively. This innovative approach could lead to more potent therapies for patients with various cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are considering or currently undergoing adoptive T cell therapy.
Not a fit: Patients with cancers that are not amenable to adoptive T cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's immune system to fight tumors.
How similar studies have performed: Other research has shown promise in enhancing T cell therapies through genetic modifications, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Carnevale, Julia C — University of California, San Francisco
- Study coordinator: Carnevale, Julia C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.